Evaluation of a cytomegalovirus glycoprotein B recombinant enzyme immunoassay to discriminate between a recent and a past infection.
Fetal damage following cytomegalovirus (CMV) intrauterine infection is mostly linked to primary infection. To differentiate primary infection from nonprimary infection, immunoglobulin M (IgM) tests are not reliable enough, and measurement of the IgG avidity appears to be the method that is the most widely used at present. In the present study the performance of the Vidas (bioMérieux) avidity assay was compared with that of a new enzyme immunoassay based on the use of a recombinant CMV glycoprotein B protein (Biotest).
D003586:Cytomegalovirus Infections / Q000378:metabolism*; D005260:Female; D005333:Fetus / Q000821:virology*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods*; D011247:Pregnancy; D011994:Recombinant Proteins / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000032:analysis*
D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus